Ovarian Cancer Clinical Trials in Houston

Showing 41-60 of 113 trials

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

NCT05292859

Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects with Solid Tumors

Gynecologic CancerColorectal CancerPancreatic Cancer+7 more

Alaunos Therapeutics7 participantsStarted Mar 2023

Houston, Texas, United States

ACTIVE_NOT_RECRUITINGPHASE3< 1 mile

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

Carcinoma, Ovarian EpithelialOvarian NeoplasmsOvarian Cancer+7 more

CanariaBio Inc.615 participantsStarted Aug 2020

Phoenix, Arizona, United States • Tucson, Arizona, United States • Concord, California, United States +145 more locations

Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Ovarian Cancer Trials in Other Cities

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

A Study of ZN-c3 in Patients With Ovarian Cancer

FPA150 in Patients With Advanced Solid Tumors

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Living WELL: A Web-Based Program for Ovarian Cancer Survivors

Other Conditions in Houston